Unveiling Shared Genetic Links between Blood Cell Traits and Cardiovascular Diseases

Abstract

Previous studies have linked blood cell traits (BCTs) to cardiovascular diseases (CVDs) risks, but the common genetic mechanisms underlying heritable phenotypes remain unclear. Our study used multiple analytical approaches including single nucleotide polymorphisms, genes, pathways, and protein targets to reveal common genetic elements. We confirmed both genome-wide and local genetic associations between BCTs and CVDs, identifying key pleiotropic loci and genes contributing to these links. Specifically, ALDH2, MAPKAPK5, and ACAD10, all located at 12q24.1, are associated with leukocyte-CVD traits. TNFSF12 at 17p13.1 and ABO at 9q34.2 correlate with platelet-CVD traits, while ZNF664 and CCDC92, also at 12q24.1, are linked to erythrocyte-CVD traits. Our findings also highlight multiple key trait-specific pathways mediating these phenotypic associations and potential therapeutic targets that may inform future clinical interventions. These insights significantly advance our understanding of the genetic interplay between BCTs and CVDs, underscoring the importance of focusing on BCTs to prevent cardiovascular conditions.

Highlights

• There were wide genetic correlation and overlap between BCT and CVD.

• Key pleiotropic loci and genes for three BCT-CVD trait pairs were identified.

• Key signature-specific pathways mediating the BCTs-CVDs association were identified.

• Potential therapeutic targets for BCTs-CVDs were identified.

eTOC blurb Kong et al. report extensive genetic correlations and genetic overlaps between blood cell traits (BCTs) and cardiovascular diseases (CVDs), revealing key pleiotropic loci and genes contributing to these associations, as well as multiple trait-specific pathways mediating these phenotypic associations. Potential therapeutic targets to inform future clinical interventions were also identified, laying the foundation for understanding the genetic interactions between BCTs and CVDs.

• Download figure
• Open in new tab

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

This study did not receive any funding.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study used only openly available GWAS summary statistics on blood cell traits and cardiovascular diseases that have originally been conducted using human data. GWAS summary statistics on BCTs are available at ftp://ftp.sanger.ac.uk/pub/project/humgen/summary_statistics/UKBB_blood_cell_traits/. GWAS summary statistics on AF, HF, and Stroke are available at the GWAS Catalog (GCST90104539, GCST009541, and GCST90104539). GWAS summary statistics on CAD and PAD are publicly available for download at the Cardiovascular Disease Knowledge Portal (CVDKP) website: https://cvd.hugeamp.org/datasets.html. GWAS summary statistics on VTE are obtained from the deCODE genetics website: https://www.decode.com/summarydata/.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes